Clinical trials: Elevated PSA
Elevated PSA, Prostate Cancer
Prospective Assessment of Image Registration for the Diagnosis of Prostate Cancer
This is a pilot study to determine cancer detection rate of conventional/systematic versus targeted biopsy methods in diagnosis of potentially lethal prostate cancer.
- Trial name
- Paired Cap (NCT02425228)
- Testing
- Targeted biopsy
- Where
- 2 sites in United States
- Volunteers
- 300 people
- Sponsor
- Jonsson Comprehensive Cancer Center
Prostate Cancer
Molecular Studies and Clinical Correlations in Human Prostatic Disease
The Genitourinary Oncology/Urology Services at Memorial Sloan-Kettering Cancer Center (MSKCC) participates in research for the control, treatment, and cure of cancer.
- Trial name
- NCT00578240
- Where
- United States
- Volunteers
- 5,290 people
- Sponsor
- Memorial Sloan Kettering Cancer Center
Prostatic Neoplasms, Neoplasm Metastasis
Combined PSMA PET/MRI for Detection of Lymph Node Metastases in High-risk Prostate Cancer Patients
For high-risk prostate cancer patients, detection of lymph node metastases is crucial to ensure optimal treatment. Standard treatment for these patients is radiotherapy or surgery.
- Trial name
- NCT04790968
- Testing
- PSMA-PET, PSMA-PET/MRI, PSMA-PET/CT
- Where
- 3 sites in Norway
- Volunteers
- 90 people
- Sponsor
- Norwegian University of Science and Technology
Prostate Cancer, Sexual Dysfunction and Infertility
Hormone Therapy in Treating Patients With Prostate Cancer
RATIONALE: Male hormones can stimulate the growth of prostate cancer cells. Hormone therapy using flutamide and finasteride may fight prostate cancer by reducing the production of male hormones.
- Trial name
- NCT00003323
- Testing
- finasteride, flutamide, quality-of-life assessment
- Where
- 43 sites in United States
- Volunteers
- 101 people
- Sponsor
- Alliance for Clinical Trials in Oncology
Prostate Cancer
Metformin for Rising PSA Remote Trial
Clinical trials are critical to informing the care of patients with cancer. However, only 3-5% of patients with cancer enroll in clinical trials.
- Trial name
- M-RePoRT (NCT02376166)
- Testing
- Metformin
- Where
- United States
- Volunteers
- 15 people, healthy volunteers welcome
- Sponsor
- Matthew Galsky
Adenocarcinoma of the Prostate
High Dose-Rate Brachytherapy and/or Intensity Modulated External Beam Radiation Therapy for Prostate Cancer
The principal objective of this study is to demonstrate that patients can safely receive combined High Dose Rate brachytherapy and Intensity-Modulated Radiation Therapy without experiencing a treatment limiting toxicity.
- Trial name
- NCT00243321
- Testing
- high dose-rate brachytherapy, intensity-modulated radiation therapy
- Where
- United States
- Volunteers
- 27 people
- Sponsor
- Virginia Commonwealth University
Prostate Cancer
Hormone Therapy in Treating Patients With Rising PSA Levels Following Radiation Therapy for Prostate Cancer
RATIONALE: Androgens can stimulate the growth of prostate cancer cells. Hormone therapy may fight prostate cancer by reducing the production of androgens.
- Trial name
- NCT00003653
- Testing
- bicalutamide, buserelin, cyproterone acetate
- Where
- 29 sites in Canada
- Volunteers
- 1,386 people
- Sponsor
- NCIC Clinical Trials Group
Castration Levels of Testosterone, Castration-Resistant Prostate Carcinoma
Molecular Features and Pathways in Predicting Drug Resistance in Patients With Metastatic Castration-Resistant Prostate Cancer Receiving Enzalutamide
This research trial studies molecular features and pathways in predicting drug resistance in patients with castration-resistant prostate cancer that has spread to other parts of the body and who are receiving enzalutamide.
- Conditions
- Castration Levels of Testosterone, Castration-Resistant Prostate Carcinoma, Prostate Adenocarcinoma, PSA Progression
- Trial name
- NCT02228265
- Testing
- Cytology Specimen Collection Procedure, Enzalutamide, Laboratory Biomarker Analysis
- Where
- 3 sites in United States
- Volunteers
- 41 people
- Sponsor
- OHSU Knight Cancer Institute
Postoperative or Postradiation Adjuvant Androgen Deprivation Therapy in Locally Advanced Prostate Cancer (High and Very High Risk) Patients
Non-Interventional Study PREVENT
This is a multicentre, non-interventional, prospective study to be carried out in representative medical institutions in order to get the information on administration of postoperative and post-radiation adjuvant androgen…
- Trial name
- PREVENT (NCT02155998)
- Where
- 14 sites in Russia
- Volunteers
- 200 people
- Sponsor
- AstraZeneca
Prostate Cancer
Study of Granulocyte-Macrophage Colony-Stimulating Factor (GM-CSF) for Patients With Rising Prostate-Specific Antigen (PSA)
This is a Phase II study to test the efficacy of exogenously administered GM-CSF in prostate cancer patients who have failed definitive local therapy, and have only serologic (PSA) evidence of progression.
- Trial name
- NCT00678054
- Testing
- GM-CSF
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- University of California, San Francisco
Prostate Cancer
Androgen Deprivation Therapy in Treating Patients With Prostate Cancer
RATIONALE: Androgens can cause the growth of prostate cancer cells. Androgen deprivation therapy may stop the adrenal glands from making androgens.
- Trial name
- NCT00110162
- Testing
- antiandrogen therapy, releasing hormone agonist therapy, orchiectomy
- Where
- 20 sites in Australia, New Zealand
- Volunteers
- 2,000 people
- Sponsor
- Peter MacCallum Cancer Centre, Australia